

IFW



ATTORNEY DOCKET NO. 13198.0007U1
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
HUESCA <i>et al.</i>)	Art Unit: Unassigned
)	
Application No. 10/579,149 ✓)	Examiner: Unassigned
International Application No. PCT/IB2004/052433)	
)	Confirmation No. 8922
U.S. Filing Date: May 12, 2006)	
International Filing Date: November 14, 2004)	
)	
For: ARYL IMIDAZOLES AND THEIR USE)	
AS ANTI-CANCER AGENTS)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

November 15, 2006

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents cited in the International Search Report for the above-referenced international application (A1-A12). Copies of cite numbers A2 thru A13 are herein enclosed.

Because the above-identified application was either filed or entered the national stage under 35 USC 371 after June 30, 2003, copies of the cited U.S. patent (A1) listed is not enclosed pursuant to 1273 OG 1.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

ATTORNEY DOCKET NO. 13198.0007U1
Application No. 10/579,149

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Christopher L. Curfman
Registration No. 52,787

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-145, on the date indicated below.


Christopher L. Curfman

November 15, 2016
Date



(Use as many sheets as necessary)

Complete if Known

Application No.	10/579,149
Filing Date	November 14, 2004
First Named Inventor	HUESCA et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	A1	3,279,918	10/18/66	Cassiers et al.	96	1	

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	A2	EP 0 812 829	12/17/97	Ontogen Corporation	
	A3	WO 00/059541	10/12/00	Sankyo Co., Ltd.	
	A4	WO 01/026467	04/19/01	Ontogen Corporation	
	A5	WO 02/024680	03/28/02	SmithKline Beecham PLC	
	A6	WO 02/072576	09/19/02	Pfizer Products, Inc.	
	A7	WO 03/032984	04/24/03	Ortho-McNeil Pharmaceutical, Inc.	
	A8	WO 03/066579	08/14/03	Axys Pharmaceuticals	
	A9	WO 03/087026	10/23/03	F. Hoffman-La Roche	
	A10	WO 97/036587	10/09/97	Merck & Co., Inc.	
	A11	WO 99/002155	01/21/99	Ontogen Corporation	
	A12	WO 99/007701	02/18/99	Sugen, Inc.	

[illegible]

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.